PresentationGiuseppe EspositoHead of Investor Relations Good morning, everyone, and thank you for joining us today. Over the next hour, we'll be presenting our full year 2025 preliminary results as well as our 2026 strategy update. As you can see from the agenda on the screen, our CEO, Matteo Del Fante, will kick off with an overview of the main achievements to date, our strategic priorities and key financial targets for 2026. Then our CFO, Camillo Greco, will take the floor to deep dive into the financials ...

Key Takeaways CPRX beat Q4 estimates with 68 cent EPS and $152.6M in revenues, up 8% year over year.Firdapse sales rose 18% to $97.6M, while Agamree revenues jumped 68% in the quarter.2026 revenue guidance of $615M-$645M reflects growth in Firdapse and Agamree sales.Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 70 cents in the year-ago quarter.Tot ...

For the quarter ended December 2025, Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million, up 7.6% over the same period last year. EPS came in at $0.68, compared to $0.70 in the year-ago quarter.The reported revenue represents a surprise of +9% over the Zacks Consensus Estimate of $140.02 million. With the consensus EPS estimate being $0.42, the EPS surprise was +60.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsJeff Del Carmen - EVP and Chief Commercial OfficerMike Kalb - EVP and CFORich Daly - President and CEONone - Company RepresentativeConference Call ParticipantsJason Dorr - Research AnalystKeith Savon - AnalystLuke Herrmann - Research AnalystPavan Patel - Biopharma Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, thank you for standing by. My name is John, and I will be you ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsJeff Del Carmen - EVP and Chief Commercial OfficerMike Kalb - EVP and CFORich Daly - President and CEONone - Company RepresentativeConference Call ParticipantsJason Dorr - Research AnalystKeith Savon - AnalystLuke Herrmann - Research AnalystPavan Patel - Biopharma Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, thank you for standing by. My name is John, and I will be you ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good morning, thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2025 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. If you would like ...

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State of jurisdiction of incorporation ...

Core Insights - Analysts project Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.42 per share, reflecting a 40% decline year over year [1] - Revenue estimates for the quarter are set at $140.02 million, indicating a 1.3% decrease from the same period last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, suggesting stability in analysts' forecasts [1] Revenue Projections - Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to be $96.43 million, representing a year-over-year increase of 16.9% [4] - The consensus for 'Revenues- Product revenue, Net- FYCOMPA' is $12.28 million, indicating a significant decline of 67.9% year over year [4] - For 'Revenues- Product revenue, Net- AGAMREE', analysts project $31.30 million, reflecting a year-over-year increase of 48.5% [4] Overall Performance - The average prediction for 'Revenues- Product revenue, net' stands at $140.01 million, showing a year-over-year change of -1.3% [5] - Over the past month, Catalyst shares have gained 0.5%, while the Zacks S&P 500 composite has decreased by 1% [5] - Catalyst holds a Zacks Rank of 3 (Hold), suggesting its performance is expected to align with the overall market in the near term [5]

CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on ...